From 9/11 to COVID-19: A Brief History of FDA Emergency Use Authorization
The history of EUA involves fundamental questions about the role of public officials, scientific expertise, and administrative norms in times of crisis.
pharmaceutical
-
Read more: From 9/11 to COVID-19: A Brief History of FDA Emergency Use Authorization -
Read more: Can Schools Require the COVID-19 Vaccine? Education, Equity, and the Courts Can Schools Require the COVID-19 Vaccine? Education, Equity, and the Courts
Given the potential legal challenges policymakers may face, legislation to remedy the COVID-19 educational crisis must be carefully drafted.
-
Read more: How Can Policymakers Encourage COVID-19 Vaccine Trials for Children? How Can Policymakers Encourage COVID-19 Vaccine Trials for Children?
We explain why COVID-19 vaccines are only just starting to be tested in children and what policymakers can do to spur pediatric vaccine trials.
-
Read more: COVID-19 and the FDA Emergency Use Authorization Power COVID-19 and the FDA Emergency Use Authorization Power
This blog post provides an overview of the FDA’s emergency authorization powers and analyzes the extent of their usage in the COVID-19 pandemic.
-
Read more: How are COVID-19 Vaccine Manufacturers Building Trust in the FDA’s Approval Process? How are COVID-19 Vaccine Manufacturers Building Trust in the FDA’s Approval Process?
Pharmaceutical companies are now also engaging the public themselves in an attempt to build trust in their products.
-
Read more: How Does Moderna’s COVID-19 Vaccine Work, and Who Is Funding Its Development? How Does Moderna’s COVID-19 Vaccine Work, and Who Is Funding Its Development?
Moderna’s vaccine works using a completely novel mechanism, unlike any other vaccine currently approved anywhere in the world.
-
Read more: COVID-19 Vaccine Advance Purchases Explained COVID-19 Vaccine Advance Purchases Explained
No vaccine for the novel coronavirus has been approved. Nevertheless, governments and organizations are making deals for tens of millions of doses.
-
Read more: What Ever Happened to NIH’s “Fair Pricing” Clause? What Ever Happened to NIH’s “Fair Pricing” Clause?
It remains to be seen whether Congress or the Administration adopt more decisive measures toward the control of drug prices than they have in the past.
-
Read more: How Do We Arrive at Fair Pricing for COVID-19 Therapies? How Do We Arrive at Fair Pricing for COVID-19 Therapies?
As the search for COVID-19 treatments and vaccines continues, questions of pricing and access are beginning to emerge.
-
Read more: How Can the US Address Coronavirus Drug Shortages? How Can the US Address Coronavirus Drug Shortages?
With the sudden spike in hospitalized patients with COVID-19 symptoms, physicians are using these drugs faster than manufacturers are making them.
